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Ten years ago, Polymeropoulos and co-workers described for the first time the existence of 
genetic linkage, a concept that reflects the finding of the place in the genome where a gene 
underlying a character is, between PD and a locus in chromosome 41. That genetic linkage was then 
characterized and, a year later, the underlying gene defect was identified: alpha-synuclein was the 
culprit of the disease in that particular family2. Today, we know that familial Parkinson disease 
(FPD) can be caused by mutations in at least 7 known genes and, possibly, at least other 4 genes 
still remain to be identified. Despite the media hype surrounding all genetic advances related to this 
prevalent disorder, the true is that there is a huge gap between our ability to understand the 
aetiology of the disease in those very few families with familial Parkinson’s disease and the known 
cause(s) of the disease in more than 90-95% of all affected individuals, those with a non-genetic 
PD3. But this grouping into two apparently separate worlds does not imply that these two types of 
PD should be considered as different entities. In effect, due to the clinical and pathological 
similarities existing between FPD and non-genetic, or at least non-monogenic, PD the knowledge of 
the genes causing the former can bring new ideas and open new doors in the research for the latter. 
Moreover, the genetic influence in non-monogenic PD cannot be neglected either. 
Epidemiological reports show that there is a genetic risk derived from the genetic makeup of the 
individuals. Thus, the risk for the disease, the response to treatment or the progression of the 
neurodegeneration are all factors that might be influenced by common genetic variability. In this 
respect, it is worth to note that this variability, unlike that causing FPD, refers to common variants 
more or less extended in the normal population and that only exert their deleterious, or their 
protective, effect when appear in combination with other genetic or environmental factors. Thus it is 
obvious that the identification of genetic factors involved in the commonest form of Parkinson 
disease is of the outmost importance for a number of reasons, some related with our knowledge of 
the disease, some related to relevant clinical aspects. Amongst the latter, the possibility of 
performing predictive genetic testing is, possibly, the most appealing of all. Having the possibility 
of predicting who and, possibly, when will an individual suffer from PD and which course his/her 
disease will take will allow clinicians to act before the disease starts once protective therapies are in 
place. 
This possibility, that today may be taken closer to Science fiction than to reality, is not such. In 
this issue of The Lancet Neurology, two separate studies analyze the effect of genes in non-
monogenic PD. Both studies follow the initial work published a few months ago by Maraganore 
and co-workers4. In that first analysis, 13 different locations in the genome were apparently related 
to the appearance of PD in the populations studied by those researchers. In genetic research, almost 
as important as an initial description of an association between a trait of interest and a gene or a 
location in the genome related to that trait is the replication of that particular finding. In this respect, 
several papers appeared in the past cast some doubt on the consistency of the initial findings5-8. In 
this issue of The Lancet Neurology two collaborative studies add some interesting data to this 
debate. The work published by Elbaz, Nelson, Payami, Ioannidis, Fiske and colleagues is a serious 
attempt to replicate the finding of Maraganore and colleagues. In this work none of the original 
thirteen locus related to PD found by Maraganore and colleagues was associated with PD by Elbaz, 
Nelson, Payami, Ioannidis, Fiske et al. One of the things that makes this study interesting is the fact 
that, for the first time, the driving force behind the study is the funding body of the original work. 
The Michael J. Fox Foundation, as part of its strong commitment to finding the cause of PD, as a 
mean to find its cure, asked a number of groups to put their forces together and to find out whether 
the initial study had found the Rosetta stone of the genetics of PD. On a separate work, Fung, 
Scholz, Matarin, Simón-Sánchez and colleagues, also failed to replicate the findings of the 
Maraganore et al work. The fact that the results of the replication did not confirmed the initial 
results can be seen as frustrating but, nevertheless, some interesting and helping lessons may be 
extracted that will help future projects of this type to be developed with higher rates of success. One 
of the lessons is that size is important. The genetic influence on PD is likely to involve many genes, 
and not all patients will suffer from their disease as a result of having inherited the same genetic 
variability. Thus, the chances to discover some or most of the genes behind PD will depend on a 
number of reasons such as their relative impact on disease risk, or the frequency of the disease-
associated allele. As both the heritability of PD9 and the penetrance of the disease is low, the size of 
the population required to detect a genetic effect should be important. Another lesson that can be 
extracted is clearly shown by the Fung, Scholz, Matarin, Simón-Sánchez and colleagues work: 
sharing of information. When we are about to witness an explosion in the number of genome-wide 
association studies (see below for a definition of this type of studies) aimed to uncover genetic 
variability related to common diseases it becomes urgent the implementation of an “Open Access” 
policy regarding the availability of data to all researchers interested in a particular subject. This is 
pioneered by the study led by A. Singleton, their complete genotype data will be made available in 
order to allow other researchers, now or in the future, to try to interpret these data in a different 
way, may be selecting groups of patients based upon certain clinical characteristics and looking for 
some genes related to their disease.  
It is also interesting to note that, despite reaching a similar conclusion, both studies are not 
comparable. Whereas Elbaz, Nelson, Payami, Ioannidis, Fiske and colleagues focus on analyzing 
the 13 regions identified by Maraganore et al. in a large population, the Fung, Scholz, Matarin, 
Simón-Sánchez and colleagues work have studied few patients but using a large number of markers. 
This approach is known as “genome-wide association” analysis. In fact, the aim of this second 
study was not to replicate Maraganore et al. findings, but to obtain (an impressive amount of) data 
and make it available; but an obvious side effect of this work was to put it in perspective with 
respect of known data. 
As a summary, the two papers published in this issue of The Lancet Neurology support the idea 
that the genetic influence in the common, non-monogenic, form of PD is largely heterogeneous and 
that no single gene is likely to have a strong effect in the relative ratio for the disease. Moreover, 
although it will not happen in the close future, starts to set the foundation of what will be routine 
medical practice in a few years from now, where use of genetic information at the multi-locus level 
will be necessary to fully understand some of the causes of the disease of a particular patient. 
Waiting for that day, researchers must be granted access to all collected data at the genetic and 
clinical level, always keeping in mind the ethical aspects associated with the use of this information, 
to take full advantage of the huge efforts made in order to obtain that data. Only through large 
collaborative efforts, including patients by the thousands, not a few hundreds, and using a dense 
map of markers, these endeavours are likely to be successful. 
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